Laurus Labs Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Laurus Labs Limited Pharmaceutical Export Portfolio Dataset — 4 Products, $3.2M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Laurus Labs Limited — Pharmaceutical Exporter Profile (2026) | 4 Products, $3.2M Trade | TransData Nexus

Product Portfolio — Top 4 by Export Value

Laurus Labs Limited exports 4 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Dolutegravir	Antiviral & HIV Medications	$1.9M	38	0.0%	9
2	Sitagliptin	Diabetes & Endocrine	$500.0K	10	0.7%	15
3	Emtricitabine	Antiviral & HIV Medications	$400.0K	8	0.3%	12
4	Tenofovir	Antiviral & HIV Medications	$400.0K	8	0.0%	13

Laurus Labs Limited exports 4 pharmaceutical products across 2 therapeutic categories with a total export value of $3.2M. The top category is Antiviral & HIV Medications (84.4% of portfolio), followed by Diabetes & Endocrine (15.6%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Laurus Labs Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

Laurus Labs Limited, established in 2005 by Dr. Satyanarayana Chava, is a Hyderabad-based Indian multinational pharmaceutical and biotechnology company. The company specializes in the development, manufacture, and sale of active pharmaceutical ingredients (APIs), generic formulations, and contract development and manufacturing services (CDMO). Its product portfolio spans therapeutic areas such as antiretrovirals, oncology, and cardiovascular diseases. As of 2022, Laurus Labs employs approximately 5,700 individuals. The company's website is www.lauruslabs.com.

2Manufacturing Facilities

Laurus Labs operates multiple manufacturing plants across India, including locations in Visakhapatnam, Hyderabad, and Bangalore. These facilities are equipped to produce a range of pharmaceutical products, including APIs and finished dosage forms. The manufacturing units have received approvals from various regulatory bodies, including the US FDA, WHO, NIP Hungary, KFDA, MHRA, TGA, and PMDA.

3Key Leadership

Dr. Satyanarayana Chava serves as the Chief Executive Officer (CEO) and Whole-Time Director of Laurus Labs Limited. Mr. Vantaram Venkata Ravi Kumar holds the position of Chief Financial Officer (CFO) and Whole-Time Director. Other key executives include Mr. B.V.R.K. Suryadevara Srinivasa Rao, President of Manufacturing and Operations, and Mr. Gogireddy Venkateswar Reddy, Vice President of Legal, Compliance Officer, and Company Secretary.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Laurus Labs Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Laurus Labs has established a significant presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's manufacturing facilities have received approvals from the US FDA, WHO, NIP Hungary, KFDA, MHRA, TGA, and PMDA, facilitating market access in these regions. In March 2020, Laurus Labs received US FDA approval to market hydroxychloroquine tablets, which were supplied for clinical trials of preventive treatment of COVID-19.

2Emerging Markets

Laurus Labs has expanded its footprint in emerging markets, including Africa, Latin America, and Southeast Asia. The company's manufacturing facilities have received approvals from the WHO, enabling access to these regions.

3Geographic Strategy

Laurus Labs has diversified its operations across multiple geographic regions, including North America, Europe, and the Rest of the World. In the fiscal year 2025, the company's revenue distribution was 20% from North America, 25% from Europe, and 55% from the Rest of the World. This diversification strategy mitigates concentration risk and positions the company to leverage growth opportunities in various markets.

Laurus Labs Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Laurus Labs' manufacturing facilities have been inspected and approved by the US FDA, facilitating the export of pharmaceutical products to the United States. The company has filed Abbreviated New Drug Applications (ANDAs) with the FDA, indicating its commitment to the US market. Additionally, Laurus Labs has filed Drug Master Files (DMFs) with the FDA, supporting the regulatory approval of its products. The company's facilities have a history of successful FDA inspections, with no critical observations reported.

2WHO & EU GMP

Laurus Labs' manufacturing facilities have received approvals from the World Health Organization (WHO) and hold European Union Good Manufacturing Practice (EU GMP) certificates. These certifications demonstrate the company's adherence to international quality standards, facilitating access to global markets.

3CDSCO & Indian Regulatory

Laurus Labs holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO) in India, authorizing the production of pharmaceutical products. The company's facilities have received approvals from state drug controllers, ensuring compliance with regional regulations. Laurus Labs has also obtained export No Objection Certificates (NOCs), enabling the export of its products to various international markets.

Laurus Labs Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Laurus Labs operates in a competitive landscape, with key competitors in overlapping categories such as antiviral and HIV medications, as well as diabetes and endocrine treatments. The company's top five exported products include Dolutegravir, Sitagliptin, Emtricitabine, and Tenofovir, with respective export values of $1.9 million, $500,000, $400,000, and $400,000. These products contribute to Laurus Labs' market presence in the antiviral and diabetes therapeutic categories.

2Key Differentiators

Laurus Labs' key differentiators include its integrated approach to pharmaceutical manufacturing, encompassing APIs, finished dosage forms, and contract development and manufacturing services. The company's strong research and development capabilities, along with its adherence to international quality standards, position it as a preferred partner for global pharmaceutical companies.

3Strategic Position

Laurus Labs is strategically positioned as a research-driven, integrated pharmaceutical company. The company's focus on complex chemistry and advanced manufacturing, including India's large Hi-Potent API capabilities, and its leadership in antiretroviral APIs, underscore its commitment to innovation and quality. The diversified portfolio, including integrated API/finished dosage form development and microbial precision fermentation through its biotech arm, reflects a strategic direction towards comprehensive pharmaceutical solutions.

Buyer Due Diligence Brief — Evaluating Laurus Labs Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Laurus Labs has a track record of consistent export volume and reliability, with a total export value of $3.2 million USD across 64 shipments. The company's portfolio concentration, with the top five products accounting for 100% of exports, indicates a focused approach to its product offerings. The company's adherence to international quality standards and successful regulatory inspections further enhance its reliability as a supplier.

2Certifications to Verify

Importers should verify the following certifications when sourcing from Laurus Labs:

FDA Approval: Confirm the company's FDA facility registrations and approved ANDAs.

WHO-GMP Certification: Ensure the manufacturing facilities hold WHO Good Manufacturing Practice certifications.

EU GMP Certification: Verify the presence of EU GMP certificates for the manufacturing facilities.

Frequently Asked Questions — Laurus Labs Limited

How many pharmaceutical products does Laurus Labs Limited export from India?

Laurus Labs Limited exports 4 pharmaceutical products across 2 therapeutic categories. The top exports are Dolutegravir ($1.9M), Sitagliptin ($500.0K), Emtricitabine ($400.0K), Tenofovir ($400.0K). Total export value is $3.2M.

What is Laurus Labs Limited's total pharmaceutical export value?

Laurus Labs Limited's total pharmaceutical export value is $3.2M, based on 64 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Laurus Labs Limited cover?

Laurus Labs Limited exports across 2 therapeutic categories. The largest are Antiviral & HIV Medications (84.4%, 3 products), Diabetes & Endocrine (15.6%, 1 products).

Get Full Laurus Labs Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.

Laurus Labs Limited

Laurus Labs Limited — Export Portfolio & Destination Treemap

Who is Laurus Labs Limited? — Company Overview & Market Position

What Does Laurus Labs Limited Export? — Product Portfolio Analysis

Top Products by Export Value

Laurus Labs Limited Therapeutic Categories — 2 Specializations